Actively Recruiting
Phase 1 Study to Evaluate Safety, Tolerability, and Drug Interactions of TBD11 in Healthy Adults with Up to 84 Days of Daily Dosing
Led by Gates Medical Research Institute · Updated on 2026-10-22
66
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are conducting a Phase 1 clinical trial to evaluate the safety, tolerability, and pharmacokinetics of TBD11, a drug given in multiple doses to healthy adult volunteers aged 18 to 55. This trial also includes a study of drug-drug interactions where TBD11 is given with either a strong CYP3A inhibitor itraconazole or inducer rifampicin. The study has three cohorts Cohort 1 receives TBD11 or placebo daily for 14 days, Cohort 2 receives a single dose of TBD11 combined with itraconazole or rifampicin in two periods, and Cohort 3 receives TBD11 or placebo daily for up to 84 days.
CONDITIONS
Brief Title
A Phase 1 Multiple Dose Trial in Healthy Adult Participants to Evaluate the Safety, Tolerability, Drug-Drug Interactions, and Pharmacokinetics of TBD11
Research Team
G
Gates MRI
G
Gates MRI
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here